NOVADAQ Announces Fourth Quarter 2015 Preliminary Unaudited Revenues and Issues 2016 Revenue Guidance

TORONTO, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Novadaq Technologies Inc. (“NOVADAQ” or the “Company”) (NVDQ) (NDQ.TO), the leading developer and provider of clinically relevant fluorescence imaging solutions for use in surgical and diagnostic procedures, announced today preliminary unaudited revenue for the fourth quarter of 2015 and provided 2016 revenue guidance ahead of its participation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. 

NOVADAQ anticipates total revenues for the fourth quarter of 2015 to be approximately $20 million, reflecting increases of approximately 54% from $13.0 million in the 2014 fourth quarter and 18% sequentially over $17.0 million in the previous quarter.

For the full year 2015, the Company anticipates total revenues to be approximately $63.8 million, representing total year-over-year revenue growth of approximately 37%.  These figures are preliminary and unaudited, and actual revenues may differ. The Company currently expects to report final 2015 financial results in February.

“As demonstrated by our sales performance in 2015, we have started moving from market creation into the adoption phase for SPY fluorescence imaging,” said Arun Menawat, NOVADAQ’s President and Chief Executive Officer.  “Moving into 2016, we expect that growth trajectory to continue.”

Click here for the full press release